MCRB — Seres Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1609809 ·
Last close
$1.41
Market Cap
$14.37M
52W High
$29.98
52W Low
$1.30
ADV30
86,812
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 0 -10,447,000 -16,286,000 65,888,000 17,528,000 44,529,000
Jun 2026 736,000 736,000 -15,466,000 4,581,000 101,588,000 15,594,000 67,054,000
Mar 2026 358,000 358,000 -20,907,000 -19,913,000 117,618,000 29,834,000 91,119,000
Dec 2025 789,000 197,000 -19,377,000 -15,335,000 138,193,000 45,766,000 93,975,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-63,941,000
Investing CF
$12,747,000
Financing CF
$15,552,000
CapEx
$-252,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.30
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,004,021,000
Inventory
—
Receivables
$12,683,000
ST Investments
—
EBIT TTM
$33,470,000
Pretax Income TTM
$-46,953,000
Interest Exp TTM
$0
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,883,000
EBITDA
$-74,778,000
Free Cash Flow
$-64,600,876
Enterprise Value
$61,827,236
Total Cash
$15,594,000
Total Debt
$56,644,000
Shares Out
10,195,031
Trailing EPS
$-5.01
Book Value
$4.63
ROE
-66.6%
ROA
-39.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 789,000 -93,971,000 5,696,000 138,193,000 93,975,000 44,218,000 1,117,000
Dec 2024 0 -121,315,000 136,000 139,810,000 126,026,000 13,784,000 -148,609,000
Dec 2023 0 -195,097,000 -113,724,000 358,600,000 403,456,000 -44,856,000 -117,354,000
Dec 2022 0 -179,914,000 -250,157,000 348,784,000 338,001,000 10,783,000 -228,816,000

TTM Snapshot

Revenues TTM
$719,000
NetIncome TTM
$-22,463,000
OpCashFlow TTM
—
Assets (Latest)
$101,588,000
Forward EPS
$-4.39

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $1.44 · call volume: 35 · put volume: 3
Expected Move to 2027-01-15: ±$1.50 (104.17%) — implied range $-0.06 – $2.94 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CTXR Citius Pharmaceuticals, Inc. $14.24M $0.52 —
KTTA Pasithea Therapeutics Corp. $14.51M $0.43 —
BOLT Bolt Biotherapeutics, Inc. $14.73M $5.65 —
MDNAF Medicenna Therapeutics Corp. $14.77M $0.16 —
INTI Inhibitor Therapeutics, Inc. $13.98M $0.08 —

News headlines (Yahoo Finance, 1h cache)

Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 12:55 · Yahoo
Seres Therapeutics: Q3 Earnings Snapshot
2026-11-04 12:12 · Yahoo
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
2026-11-04 12:00 · Yahoo
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
2026-11-03 12:00 · Yahoo
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
2026-10-15 11:00 · Yahoo
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-08 22:00 · Yahoo
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
2026-09-07 08:27 · Yahoo
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 11:00 · Yahoo
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
2026-08-05 11:00 · Yahoo
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
2026-07-10 18:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.